CADTH Canadian Drug Expert Committee recommendation: Insulin degludec and liraglutide (Xultophy -- Novo Nordisk Canada Inc.) indication : adjunct to lifestyle modifications, for the once-daily treatment of adults with type 2 diabetes mellitus (T2DM) to improve glycemic control in combination with metformin, with or without sulfonylurea, when these combined with basal insulin (less than 50 units daily) or liraglutide (less than or equal to 1.8 mg daily), do not provide adequate glycemic control

The CADTH Canadian Drug Expert Committee (CDEC) recommends that insulin degludec and liraglutide (IDegLira) should be reimbursed as an adjunct to lifestyle modification, for the once-daily treatment of adults with T2DM to improve glycemic control in combination with metformin (MET), with or without...

Full description

Bibliographic Details

Corporate Authors:	CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) CADTH October 2019, 2019
Edition:	Version: 1.0
Series:	CADTH common drug review
Subjects:	Insurance, Health, Reimbursement Drug Combinations Canada Blood Glucose / Drug Effects Hypoglycemic Agents / Therapeutic Use Diabetes Mellitus, Type 2 / Drug Therapy Liraglutide / Therapeutic Use Insulin, Long-acting / Therapeutic Use
Online Access:	http://www.ncbi.nlm.nih.gov/books/NBK554707
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa